Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In Southeast Asia, some types of the malaria parasite develop resistance to the drug combinations used to cure and prevent the disease. If this drug resistance spread to Africa, it’d be a disaster. Fortunately, partners on the front lines are finding ways to fight back. Watch this video about the amazing work our team of SMRU researchers is doing to combat drug resistance in Thailand.

The Shoklo Malaria Research Unit (SMRU) was established in 1986 as a centre for epidemiological study into the treatment and prevention of resistant malaria among refugee camps on the Thai-Burma border. At the time, malaria was the most serious health problem facing the displaced population living along the border and the primary cause of death, representing over 45% of out-patient consultations.

Currently 130,000 people live in refugee camps along the Thai-Burma border. The work carried out by SMRU over the past 20 years has improved therapeutics for malaria and relegated malaria from being the single most important medical problem in these camps, to a rare cause of illness and death amongst refugees.

Researchers at SMRU continue to monitor, treat and control malaria, both within the camps and amongst the communities of Burmese migrant workers, who live outside the camps.

Video transcript

It’s one of the most stunning things to say that this little mosquito kills almost a million people every year. Most of those deaths are from malaria. We study mosquitoes in the lab where we grow them, and researchers, volunteers taking their own arm in and feeding them with their own blood. One of the partners and foundations we work with is the Shoklo Malaria Research Unit in Thailand.

When you are infected with malaria, you can take drugs that clear it from your body. Our best drug, artemisinin combination therapy ACT, unfortunately right now in Southeast Asia we are seeing resistance emerge. And that's very scary because if that mutation left Southeast Asia and moved to Africa, in the place where most malaria deaths take place, and where these new drugs being so valuable, they will stop working. A child experiencing cerebral malaria is an awful thing to watch because their brain is being damaged, and they have seizures, and you have to move very quickly. I’ve been in those wards, you can see the sweatiness, that incredible fever that the child’s experiencing.

Along the Myanmar Thailand border, many people work in the forest. These workers often are bringing malaria back at home. One thing that's confusing about malaria, is if you've been exposed enough, your symptoms go way way down, yet we want to cure those people, so that they're not a source of the disease. We've got a team of health workers called the malaria elimination task force, and they are on the frontline. They’re trying to find the cases and treat everyone.

I'm Gilles Delmas, I’m the director of the Malaria Elimination Task Force. Years ago, there were lots of malaria cases. Anybody around here would have several malaria attacks in a year, sometimes more than one a month. The situation has got much better, and the transmission is much lower than what it was. The problem is that the medicines we're using now to control malaria, to treat the patients, are showing signs of resistance, and we know that within the next two to five years, the medicines we’re using now will be useless.

So the world is investing in these workers in Southeast Asia to go find malaria and get rid of it. If we can get rid of it there, it won't have a chance to spread to other locations. We reach out to the people and communities, creating health post workers. These are people who don't have medical training, they're just local villagers who volunteer to help out with this effort. They receive kits with the diagnostic equipment, and the local people trust them. They know them and if the test comes back positive, they'll be able to give them the drugs immediately. In the areas where malaria parasite factions are very very hot, or even asking some villages all of the people there to take the drug to clear out the malaria. If we do it with the right coverage level, malaria will die out in that region. If we do this well, we’ll stop drug resistant malaria from spreading, and we’ll learn how you can get rid of malaria in villages, and use that on a global basis.

There’s just so many mosquitoes.

Similar stories

All-nighter: staying up to fight malaria

Featured in Nature, Victor Chaumeau collects mosquitoes in Myanmar to better understand how to control malaria.

ASM Editor in conversation with Nick White

Malaria continues to be a major killer, particularly in sub-Saharan Africa, affecting the world’s most vulnerable populations with more than 500,000 deaths per year, most of them African children. Emergence of resistance to antimalarial drugs is major public health issue. American Society for Microbiology Editor Dr Cesar Arias discusses with Professor Sir Nick White the latest information on this rapidly evolving field.

AMR and scrub typhus among Chiangrai Unit's research priorities

Which infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.

Arjen Dondorp, Peter Horby and Rose McGready elected Academy of Medical Sciences Fellows

"Although it is hard to look beyond the pandemic right now," says President of the Academy of Medical Sciences Professor Dame Anne Johnson, "I want to stress how important it is that the Academy Fellowship represents the widest diversity of biomedical and health sciences. The greatest health advances rely on the findings of many types of research, and on multidisciplinary teams and cross-sector and global collaboration."

Researchers call for access to Ivermectin for young children

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.